IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i17p10975-d905252.html
   My bibliography  Save this article

Excellent Response to OnabotulinumtoxinA: Different Definitions, Different Predictors

Author

Listed:
  • Raffaele Ornello

    (Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L’Aquila, Via Vetoio 1 Coppito, 67100 L’Aquila, Italy
    These authors contributed equally to the work and are shared first authors.)

  • Carlo Baraldi

    (Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, Department of Specialist Medicines, AOU Policlinico di Modena, 41125 Modena, Italy
    These authors contributed equally to the work and are shared first authors.)

  • Fayyaz Ahmed

    (Department of Neurosciences, Hull University Teaching Hospitals, Hull HU3 2JZ, UK)

  • Andrea Negro

    (Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant’Andrea Hospital, Sapienza University, 00189 Rome, Italy)

  • Anna Maria Miscio

    (Headache Center, Unit of Neurology, Fondazione IRCCS “Casa Sollievo Della Sofferenza”, 71013 San Giovanni Rotondo, Italy)

  • Antonio Santoro

    (Headache Center, Unit of Neurology, Fondazione IRCCS “Casa Sollievo Della Sofferenza”, 71013 San Giovanni Rotondo, Italy)

  • Alicia Alpuente

    (Headache Unit, Department of Neurology, Vall D’Hebron University, 08035 Barcelona, Spain
    Headache and Neurological Pain Research Group, Vall D’Hebron Institute of Research (VHIR), Department of Medicine, Universitat Autonoma de Barcelona, 08193 Barcelona, Spain)

  • Antonio Russo

    (Headache Center, Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania “Luigi Vanvitelli”, 81100 Naples, Italy)

  • Marcello Silvestro

    (Headache Center, Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania “Luigi Vanvitelli”, 81100 Naples, Italy)

  • Sabina Cevoli

    (IRCCS Istituto delle Scienze Neurologiche di Bologna, 40139 Bologna, Italy)

  • Nicoletta Brunelli

    (Headache and Neurosonology Unit, Campus Bio-Medico University Hospital, 00128 Rome, Italy)

  • Fabrizio Vernieri

    (Headache and Neurosonology Unit, Campus Bio-Medico University Hospital, 00128 Rome, Italy)

  • Licia Grazzi

    (Headache Center, Neuroalgology Department, IRCCS Foundation “Carlo Besta” Neurological Institute, Via Celoria, 11, 20133 Milan, Italy)

  • Luca Pani

    (Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, Department of Specialist Medicines, AOU Policlinico di Modena, 41125 Modena, Italy
    Pharmacology Unit, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41121 Modena, Italy
    Department of Psychiatry and Behavioral Sciences, University of Miami, Coral Gables, FL 33146, USA
    VeraSci, Durham, NC 27707, USA)

  • Anna Andreou

    (Headache Service, Guy’s and St Thomas’ NHS Foundation Trust, London SE1 7EH, UK)

  • Giorgio Lambru

    (Headache Service, Guy’s and St Thomas’ NHS Foundation Trust, London SE1 7EH, UK)

  • Ilaria Frattale

    (Child Neurology and Psychiatry Unit, Systems Medicine Department, Tor Vergata University, 00133 Rome, Italy)

  • Katharina Kamm

    (Department of Neurology, Ludwig Maximilians University München, 80539 Munich, Germany)

  • Ruth Ruscheweyh

    (Department of Neurology, Ludwig Maximilians University München, 80539 Munich, Germany)

  • Marco Russo

    (Headache Center, Neurology Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS Di Reggio Emilia, 42122 Reggio Emilia, Italy)

  • Paola Torelli

    (Headache Center, University of Parma, 43121 Parma, Italy)

  • Elena Filatova

    (Department of Neurology, Institute for Postgraduate Education, Sechenov First Moscow State Medical University (Sechenov University), 119435 Moscow, Russia)

  • Nina Latysheva

    (Department of Neurology, Institute for Postgraduate Education, Sechenov First Moscow State Medical University (Sechenov University), 119435 Moscow, Russia)

  • Anna Gryglas-Dworak

    (Headache Center Wroclaw, 50-307 Wrocław, Poland)

  • Marcin Straburzyński

    (Department of Family Medicine and Infectious Diseases, University of Warmia and Mazury, 10-719 Olsztyn, Poland)

  • Calogera Butera

    (Neurophysiology Service, IRCCS San Raffaele Scientific Institute, 71013 Milan, Italy)

  • Bruno Colombo

    (Neurology Unit, IRCCS San Raffaele Scientific Institute, 71013 Milan, Italy)

  • Massimo Filippi

    (Neurophysiology Service, IRCCS San Raffaele Scientific Institute, 71013 Milan, Italy
    Neurology Unit, IRCCS San Raffaele Scientific Institute, 71013 Milan, Italy
    Neurorehabilitation Unit, IRCCS San Raffaele Scientific Institute, 71013 Milan, Italy)

  • Patricia Pozo-Rosich

    (Headache Unit, Department of Neurology, Vall D’Hebron University, 08035 Barcelona, Spain
    Headache and Neurological Pain Research Group, Vall D’Hebron Institute of Research (VHIR), Department of Medicine, Universitat Autonoma de Barcelona, 08193 Barcelona, Spain)

  • Paolo Martelletti

    (Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant’Andrea Hospital, Sapienza University, 00189 Rome, Italy)

  • Simona Guerzoni

    (Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, Department of Specialist Medicines, AOU Policlinico di Modena, 41125 Modena, Italy
    These authors contributed equally to the work and are shared last authors.)

  • Simona Sacco

    (Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L’Aquila, Via Vetoio 1 Coppito, 67100 L’Aquila, Italy
    These authors contributed equally to the work and are shared last authors.)

Abstract

The identification of patients who can benefit the most from the available preventive treatments is important in chronic migraine. We explored the rate of excellent responders to onabotulinumtoxinA in a multicenter European study and explored the predictors of such response, according to different definitions. A pooled analysis on chronic migraineurs treated with onabotulinumtoxinA and followed-up for, at least, 9 months was performed. Excellent responders were defined either as patients with a ≥75% decrease in monthly headache days (percent-based excellent responders) or as patients with <4 monthly headache days (frequency-based excellent responders). The characteristics of excellent responders at the baseline were compared with the ones of patients with a <30% decrease in monthly headache days. Percent-based excellent responders represented about 10% of the sample, whilst frequency-based excellent responders were about 5% of the sample. Compared with non-responders, percent-based excellent responders had a higher prevalence of medication overuse and a higher excellent response rate even after the 1st and the 2nd injection. Females were less like to be frequency-based excellent responders. Chronic migraine sufferers without medication overuse and of female sex may find fewer benefits with onabotulinumtoxinA. Additionally, the excellent response status is identifiable after the first cycle.

Suggested Citation

  • Raffaele Ornello & Carlo Baraldi & Fayyaz Ahmed & Andrea Negro & Anna Maria Miscio & Antonio Santoro & Alicia Alpuente & Antonio Russo & Marcello Silvestro & Sabina Cevoli & Nicoletta Brunelli & Fabri, 2022. "Excellent Response to OnabotulinumtoxinA: Different Definitions, Different Predictors," IJERPH, MDPI, vol. 19(17), pages 1-12, September.
    • Handle: RePEc:gam:jijerp:v:19:y:2022:i:17:p:10975-:d:905252
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/17/10975/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/19/17/10975/
    Download Restriction: no
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:17:p:10975-:d:905252. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.